Page last updated: 2024-12-07
4',6-dichloroflavan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4',6-dichloroflavan: antirhinovirus cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 126331 |
CHEMBL ID | 29441 |
SCHEMBL ID | 4461737 |
MeSH ID | M0097560 |
Synonyms (16)
Synonym |
---|
73110-56-2 |
6-chloro-2-(4-chlorophenyl)chromane |
bw683c |
4',6-dichloroflavan |
2h-1-benzopyran, 6-chloro-2-(4-chlorophenyl)-3,4-dihydro- |
bw-683c |
brn 5750146 |
6,4'-dichloroflavan |
bw 683c |
2h-1-benzopyran, 3,4-dihydro-6-chloro-2-(4-chlorophenyl)- |
3,4-dihydro-6-chloro-2-(4-chlorophenyl)-2h-1-benzopyran |
CHEMBL29441 |
SCHEMBL4461737 |
6-chloro-2-(4-chlorophenyl)-3,4-dihydro-2h-1-benzopyran |
DTXSID80993860 |
6,4'-dichloroflavan; bw 683c; bw 683c77 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Mice dosed orally with 200 mg/kg of 1c or 1h exhibited serum levels well in excess of each compound's MIC50, indicating that some analogues have the potential to be orally effective drugs." | ( 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity. Bargar, TM; Daniel, JK; Dulworth, JK; Kenny, MT; Massad, R; Sargent, RN; Wilson, T, 1986) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (41)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID200189 | In vitro activity against Rhinovirus type 1B by plaque inhibition assay. | 1988 | Journal of medicinal chemistry, Oct, Volume: 31, Issue:10 | 9-Benzyl-6-(dimethylamino)-9H-purines with antirhinovirus activity. |
AID200199 | In vitro anti-picornavirus activity against Rhinovirus type-2. | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Isoxazoles with antipicornavirus activity. |
AID511348 | Antiviral activity against Human enterovirus 71 infected in human Hep2 cells at maximum non-cytotoxic concentration after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID1063591 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 3 days by XTT assay | 2014 | Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3 | Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones. |
AID86997 | Concentration required to reduce Rhino virus type 9 induced plaque formation in HeLa cell culture to 50% of control | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity. |
AID1063586 | Antiviral activity against HRV 1B infected in human HeLa cells assessed as reduction in plaque number at maximum non-cytotoxic concentration after 3 days by neutral red assay | 2014 | Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3 | Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones. |
AID424993 | Therapeutic index, ratio of TC50 for human HeLa Ohio cells to IC50 for HRV1B infected in human HeLa Ohio cells | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives. |
AID86992 | Concentration required to reduce Rhino virus type 1A induced plaque formation in HeLa cell culture to 50% of control | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity. |
AID199858 | In vitro antiviral activity against Rhinovirus type-2 | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID1439647 | Antiviral activity against HRV 14 infected in human HeLa cells up to MNCC after 72 hrs by plaque reduction assay | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7 | 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors. |
AID1439635 | Antiviral activity against HRV 1B infected in human HeLa cells after 72 hrs by plaque reduction assay | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7 | 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors. |
AID86823 | Lowest concentration at which the effect on HeLa cell colony formation became apparent. | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity. |
AID86994 | Concentration required to reduce Rhino virus type 64 induced plaque formation in HeLa cell culture to 50% of control | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | 3,4-Dihydro-2-phenyl-2H-pyrano[2,3-b]pyridines with potent antirhinovirus activity. |
AID162259 | In vitro anti-picornavirus activity against Poliovirus type-2. | 1985 | Journal of medicinal chemistry, Jun, Volume: 28, Issue:6 | Isoxazoles with antipicornavirus activity. |
AID103315 | Compound was tested for anti-rhinovirus type 1B activity in a plaque inhibition assay using monolayers of M-HeLa cells | 1989 | Journal of medicinal chemistry, Jan, Volume: 32, Issue:1 | Synthesis and structure-activity relationships of 2-substituted-6-(dimethylamino)-9-(4-methylbenzyl)-9H-purines with antirhinovirus activity. |
AID634250 | Therapeutic index, ratio of TC50 for human HeLa cells to IC50 for Human rhinovirus 1B infected in human HeLa cells | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. |
AID511347 | Antiviral activity against Human enterovirus 71 infected in human Hep2 cells after 2 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID1439634 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability by XTT assay | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7 | 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors. |
AID424987 | Cytotoxicity against human HeLa Ohio cells after 3 days by XTT assay | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives. |
AID332519 | Antiviral activity against Rhinovirus 1B infected in human HeLa cells assessed as reduction in plaque formation per plate after 72 hrs | 1994 | Journal of natural products, May, Volume: 57, Issue:5 | Isolation of antirhinoviral sesquiterpenes from ginger (Zingiber officinale). |
AID1063590 | Antiviral activity against HRV 1B infected in human HeLa cells assessed as reduction in plaque number after 3 days by neutral red assay | 2014 | Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3 | Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones. |
AID1063589 | Selectivity index, ratio of CC50 for human HeLa cells to IC50 for HRV 1B infected in human HeLa cells | 2014 | Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3 | Synthesis and anti-rhinovirus activity of novel 3-[2-(pyridinyl)vinyl]substituted -2H-chromenes and -4H-chromen-4-ones. |
AID1439636 | Selectivity index, ratio of CC50 for human HeLa cells to IC50 for HRV 1B infected in human HeLa cells | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7 | 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors. |
AID511340 | Cytotoxicity against human HeLa cells assessed as maximum non-cytotoxic concentration after 3 days by XTT assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID634248 | Cytotoxicity against human HeLa cells after 3 days by XTT based ELISA reader | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. |
AID200198 | Evaluated for inhibitory activity against rhinovirus type 5 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Antirhinovirus activity of 6-anilino-9-benzyl-2-chloro-9H-purines. |
AID634249 | Antiviral activity against Human rhinovirus 1B infected in human HeLa cells assessed as inhibition of virus induced-plaque formation after 3 days by neutral red-based plaque reduction assay | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. |
AID200197 | Evaluated for inhibitory activity against rhinovirus type 4 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Antirhinovirus activity of 6-anilino-9-benzyl-2-chloro-9H-purines. |
AID511341 | Antiviral activity against Human rhinovirus 1B infected in human HeLa cells after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID115933 | In vitro antiviral activity against mice infected intracerebrally with Poliovirus type-2; Inactive | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating. |
AID200195 | Evaluated for inhibitory activity against rhinovirus type 2 | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Antirhinovirus activity of 6-anilino-9-benzyl-2-chloro-9H-purines. |
AID1439633 | Cytotoxicity against human HeLa cells assessed as changes in morphology after 3 days by microscopic method | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7 | 3-Phenylalkyl-2H-chromenes and -chromans as novel rhinovirus infection inhibitors. |
AID424989 | Antiviral activity against HRV 1B infected in human HeLa Ohio cells assessed as reduction in viral plaque formation after 3 days by neutral red uptake assay | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives. |
AID511344 | Antiviral activity against Human rhinovirus 14 infected in human HeLa cells at maximum non-cytotoxic concentration after 3 days by plaque reduction assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID634247 | Cytotoxicity against human HeLa cells after 3 days by microscopic analysis | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. |
AID634254 | Antiviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as inhibition of virus induced-plaque formation at 25 uM after 3 days by neutral red-based plaque reduction assay | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Design, synthesis and in vitro evaluation of novel chroman-4-one, chroman, and 2H-chromene derivatives as human rhinovirus capsid-binding inhibitors. |
AID511339 | Cytotoxicity against human HeLa cells after 3 days by XTT assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID511346 | Cytotoxicity against human Hep2 cells assessed as maximum non-cytotoxic concentration after 3 days by XTT assay | 2010 | Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17 | New 4H-chromen-4-one and 2H-chromene derivatives as anti-picornavirus capsid-binders. |
AID200192 | Inhibitory activity against rhinovirus type 1B | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Antirhinovirus activity of 6-anilino-9-benzyl-2-chloro-9H-purines. |
AID424991 | Antiviral activity against HRV 14 infected in human HeLa Ohio cells assessed as reduction in viral plaque formation after 3 days by neutral red uptake assay | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives. |
AID424988 | Cytotoxicity against human HeLa Ohio cells assessed as maximal non-cytotoxic concentration after 3 days by XTT assay | 2009 | Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10 | Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (26)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 17 (65.38) | 18.7374 |
1990's | 3 (11.54) | 18.2507 |
2000's | 1 (3.85) | 29.6817 |
2010's | 4 (15.38) | 24.3611 |
2020's | 1 (3.85) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.12) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (11.11%) | 5.53% |
Reviews | 3 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (77.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |